%0 Journal Article
%A Kolwelter, Julie
%A Kannenkeril, Dennis
%A Linz, Peter
%A Jung, Susanne
%A Nagel, Armin M
%A Bosch, Agnes
%A Ott, Christian
%A Bramlage, Peter
%A Nöh, Lisa
%A Schiffer, Mario
%A Uder, Michael
%A Achenbach, Stephan
%A Schmieder, Roland E
%T The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
%J Clinical research in cardiology
%V 112
%N 1
%@ 0300-5860
%C Berlin
%I Springer
%M DKFZ-2022-02629
%P 134-144
%D 2023
%Z 2023 Jan;112(1):134-144
%X Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patients with CHF.In a double-blind, randomised (2:1), placebo-controlled, parallel-group, clinical trial, 74 patients with NYHA class II-III CHF and an ejection fraction of 49
%K Chronic heart failure (Other)
%K Empagliflozin (Other)
%K Magnetic resonance imaging (Other)
%K SGLT2 inhibitor (Other)
%K Sodium (Other)
%K Tissue sodium content (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36289063
%R 10.1007/s00392-022-02119-7
%U https://inrepo02.dkfz.de/record/182408